Dehydrocorydalin

Research use only, not for human use.

Dehydrocorydaline exerts anti-metastatic potential via suppression of MMPs and Bcl-2 signaling in NSCLC cells.

Dehydrocorydaline exerts anti-metastatic potential via suppression of MMPs and Bcl-2 signaling in NSCLC cells. Dehydrocorydaline stimulates p38 MAPK activation, which can enhance heterodimerization of MyoD and E proteins, thus resulting in MyoD activation and myoblast differentiation. Dehydrocorydaline shows antiplatelet effects, it inhibits thrombin-induced platelet aggregation in a low dose ( IC50= 34.914?ug/mL). Dehydrocorydaline has anti-inflammatory and antinociceptive effects. Dehydrocorydaline inhibits MCF-7 cell proliferation by inducing apoptosis mediated by regulating Bax/Bcl-2, activating caspases as well as cleaving PARP.

——

——

13-Methylpalmatine

Others

Other Targets

Others

Cancer

——

30045-16-0

366.43

C22H24NO4+

>98% (HPLC)

In Vitro:?DMSO : 25 mg/mL (68.23 mM)

CC1=C2C=CC(=C(C2=C[N+]3=C1C4=CC(=C(C=C4CC3)OC)OC)OC)OC

——

(-20℃)

With Ice Pack

≥ 2 years